0001209191-23-038154.txt : 20230616
0001209191-23-038154.hdr.sgml : 20230616
20230616201444
ACCESSION NUMBER: 0001209191-23-038154
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230615
FILED AS OF DATE: 20230616
DATE AS OF CHANGE: 20230616
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Jaen Juan C.
CENTRAL INDEX KEY: 0001422996
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38419
FILM NUMBER: 231023007
MAIL ADDRESS:
STREET 1: 850 MAUDE AVENUE
CITY: MOUNTAIN VIEW
STATE: CA
ZIP: 94043
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Arcus Biosciences, Inc.
CENTRAL INDEX KEY: 0001724521
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 473898435
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3928 POINT EDEN WAY
CITY: HAYWARD
STATE: CA
ZIP: 94545
BUSINESS PHONE: (510) 694-6200
MAIL ADDRESS:
STREET 1: 3928 POINT EDEN WAY
CITY: HAYWARD
STATE: CA
ZIP: 94545
4
1
doc4.xml
FORM 4 SUBMISSION
X0407
4
2023-06-15
0
0001724521
Arcus Biosciences, Inc.
RCUS
0001422996
Jaen Juan C.
C/O ARCUS BIOSCIENCES, INC.
3928 POINT EDEN WAY
HAYWARD
CA
94545
1
1
0
0
President
1
Common Stock
2023-06-15
4
G
0
6000
0.00
D
318682
D
Common Stock
2023-06-16
4
D
0
4820
19.35
D
313862
D
Common Stock
1222240
I
By Trust
Represents a gift to a family trust over which the reporting person has neither voting nor investment control.
Represents shares sold by the Issuer on the reporting person's behalf to cover tax withholding obligations in connection with the vesting of certain RSUs (previously reported in Table I) following the date of grant. The sale occurred automatically pursuant to the Issuer's equity administration policy, which was implemented on January 15, 2021, and does not represent a discretionary trade by the reporting person.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $18.86 to $19.77, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
/s/ Carolyn Tang, Attorney-in-Fact
2023-06-16